Strides Pharma Science Limited (NSE:STAR) — Market Cap & Net Worth
Market Cap & Net Worth: Strides Pharma Science Limited (STAR)
Strides Pharma Science Limited (NSE:STAR) has a market capitalization of $1.03 Billion (Rs94.80 Billion) as of August 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #8703 globally and #438 in its home market, demonstrating a 0.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Strides Pharma Science Limited's stock price Rs1028.50 by its total outstanding shares 92172714 (92.17 Million). See Strides Pharma Science Limited (STAR) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Strides Pharma Science Limited Market Cap History: 2015 to 2026
Strides Pharma Science Limited's market capitalization history from 2015 to 2026. Data shows change from $1.12 Billion to $1.03 Billion (-0.86% CAGR).
Index Memberships
Strides Pharma Science Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$152.67 Billion | 0.67% | #51 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.30 Trillion | 0.03% | #363 of 750 |
Weight: Strides Pharma Science Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Strides Pharma Science Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Strides Pharma Science Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Strides Pharma Science Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.18x
Strides Pharma Science Limited's market cap is 0.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $722.36 Million | $27.55 Billion | $1.81 Billion | 0.03x | 0.40x |
| 2018 | $435.75 Million | $28.45 Billion | -$457.92 Million | 0.02x | N/A |
| 2019 | $356.06 Million | $21.20 Billion | $523.08 Million | 0.02x | 0.68x |
| 2020 | $868.06 Million | $26.83 Billion | $241.47 Million | 0.03x | 3.59x |
| 2021 | $443.30 Million | $32.80 Billion | $2.55 Billion | 0.01x | 0.17x |
| 2022 | $346.92 Million | $30.59 Billion | -$4.60 Billion | 0.01x | N/A |
| 2023 | $645.99 Million | $36.68 Billion | -$2.21 Billion | 0.02x | N/A |
| 2024 | $657.30 Million | $38.28 Billion | -$1.20 Billion | 0.02x | N/A |
| 2025 | $897.48 Million | $44.75 Billion | $4.05 Billion | 0.02x | 0.22x |
| 2026 | $1.03 Billion | $48.59 Billion | $5.56 Billion | 0.02x | 0.18x |
Competitor Companies of STAR by Market Capitalization
Companies near Strides Pharma Science Limited in the global market cap rankings as of August 4, 2026.
Key companies related to Strides Pharma Science Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Strides Pharma Science Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Strides Pharma Science Limited's market cap moved from $1.12 Billion to $ 1.03 Billion, with a yearly change of -0.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.03 Billion | +14.23% |
| 2025 | Rs897.48 Million | +36.54% |
| 2024 | Rs657.30 Million | +1.75% |
| 2023 | Rs645.99 Million | +86.21% |
| 2022 | Rs346.92 Million | -21.74% |
| 2021 | Rs443.30 Million | -48.93% |
| 2020 | Rs868.06 Million | +143.80% |
| 2019 | Rs356.06 Million | -18.29% |
| 2018 | Rs435.75 Million | -39.68% |
| 2017 | Rs722.36 Million | -22.11% |
| 2016 | Rs927.46 Million | -17.32% |
| 2015 | Rs1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Strides Pharma Science Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more